Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Motor Activity 1Melanoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Clinical Trials as Topic × Clear all
NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT01571401 2013-06-19

TRACKS

University of Alberta

Phase 2 Completed
32 enrolled

Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡